gefitinib has been researched along with paxilline in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (paxilline) | Trials (paxilline) | Recent Studies (post-2010) (paxilline) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 2,097 | 3 | 790 |
| Protein | Taxonomy | gefitinib (IC50) | paxilline (IC50) |
|---|---|---|---|
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | 33.55 | |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Oryctolagus cuniculus (rabbit) | 5 | |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Homo sapiens (human) | 5 | |
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 | Homo sapiens (human) | 5 | |
| BZLF2 | Human herpesvirus 4 type 2 (Epstein-Barr virus type 2) | 2.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrow, D; Gee, J; Green, TP; Hiscox, S; Morgan, L; Nicholson, RI | 1 |
1 other study(ies) available for gefitinib and paxilline
| Article | Year |
|---|---|
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Focal Adhesion Kinase 1; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Paxillin; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; Tamoxifen | 2006 |